AI Article Synopsis

  • A study evaluated the safety and efficacy of desoximetasone 0.25% and 0.05% topical sprays, focusing on their potential to cause photoallergic reactions when exposed to UV light.
  • 53 participants applied the treatments over three weeks, with some areas irradiated and others not, to monitor any adverse skin reactions.
  • Results showed no evidence of photosensitization from either concentration of the desoximetasone sprays, suggesting they are safe for patients with conditions like eczema or psoriasis who undergo UV light therapy.

Article Abstract

Purpose: Desoximetasone 0.25% topical spray is a novel formulation that has not been tested or approved for safety and efficacy. The primary objective was to determine the potential of desoximetasone 0.25 and 0.05% topical sprays, as well as a vehicle to induce photoallergic skin reaction after repeated topical application and irradiation to the skin using a controlled photopatch testing procedure.

Materials And Methods: 53 subjects completed the study, each with six application sites (two of each treatment), three of which were irradiated and three non-irradiated, for an induction period of three weeks and then challenge period at week 6.

Results: Desoximetasone 0.25 and 0.05%, as well as vehicle showed no evidence of potential to induce photosensitization. There was statistically significantly greater irritation at the vehicle irradiated site in comparison to the irradiated treatment area of desoximetasone 0.25% (p = .005) and the irradiated treatment area of desoximetasone 0.05% (p = .008).

Conclusion: Our results suggest that regular treatment with desoximetasone 0.25 and 0.05% spray, followed by UV light exposure does not induce photosensitization or photo-irritation. These findings increase confidence for the use of this topical spray in eczema or psoriasis patients who may also be receiving UV light therapy and may contribute to the clinical management of these patients.

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2017.1395803DOI Listing

Publication Analysis

Top Keywords

desoximetasone 025%
12
desoximetasone 025
12
025 005%
12
induce photoallergic
8
photoallergic skin
8
skin reaction
8
topical spray
8
well vehicle
8
induce photosensitization
8
irradiated treatment
8

Similar Publications

Patients preferences for different corticosteroid vehicles are highly variable.

J Dermatolog Treat

March 2020

Department of Dermatology, Wake Forest School of Medicine, Center for Dermatology Research, Winston-Salem, NC,USA.

Topical corticosteroids, available in an array of vehicles are used to control a variety of inflammatory skin diseases. Patients preferences for different vehicles may affect their willingness to use treatment. We assess corticosteroid vehicle preference and potential impact of topical characteristics on adherence and quality of life in patients with psoriasis.

View Article and Find Full Text PDF

Spectrophotometric determination of desoximetasone in ointment using 1,4-dihydrazinophthalazine.

J Pharm Biomed Anal

June 1996

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Belgrade, Yugoslavia.

The proposed method is based on coloured hydrazone formation with 1,4-dihydrazinophthalazine as a reagent. Heating at 85 degrees C for 2 h was found necessary to ensure optimal hydrazone formation in the presence of hydrochloric acid. The yellow hydrazone product has an absorption maximum at 380 nm.

View Article and Find Full Text PDF

In a double-blind study on 22 patients affected by neurodermitis the action of two ointmes was studied. Both possess an activity in controlling the clinical and histological manifestations of the disease. Desoximethasone (red labelled tubes) is very usefull in controlling pruritus and, histologically, the epidermal component of the lesions.

View Article and Find Full Text PDF

A randomized double-blind left-right comparative trial was carried out between a new steroid Desoximetason 0,25% (Ibaril) and fluocinolone acetonide 0,025% cream. Evaluation of symptoms on 50 patients suffering from endogenous eczema was recorded after 1, 2, 3 and 4 weeks. There was a significantly better effect of Ibaril compared to Fluocinolone-acetonide as judged by the observer during the 1st, 3rd and 4th week of treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!